Sample ID
|
Gender
|
Age
|
Subtype
|
Tumor grade
|
TNM stage
|
AJCC stagea
|
OS (months)
|
DFS (months)
|
Outcome
|
---|
1
|
Male
|
76
|
ccRCC
|
G2
|
T3aN0M0
|
III
|
34
|
34
|
Death
|
2
|
Male
|
74
|
ccRCC
|
G2
|
T1aN0M0
|
I
|
32
|
32
|
Death
|
3
|
Male
|
31
|
ccRCC
|
G3
|
T3aN0M0
|
III
|
63
|
63
|
Death
|
4
|
Male
|
74
|
ccRCC
|
G2
|
T1aN0M0
|
I
|
62
|
62
|
Death
|
5
|
Male
|
54
|
ccRCC
|
G2
|
T1aN0M0
|
I
|
57
|
57
|
Death
|
6
|
Male
|
62
|
ccRCC
|
G2
|
T1aN0M0
|
I
|
76
|
64
|
Survival (metastasis)
|
7
|
Female
|
40
|
ccRCC
|
G3
|
T3bN0M0
|
III
|
74
|
24
|
Survival (metastasis)
|
8
|
Female
|
57
|
ccRCC
|
G2
|
T1aN0M0
|
I
|
74
|
24
|
Survival (metastasis)
|
9
|
Male
|
56
|
ccRCC
|
G2
|
T3aN0M0
|
III
|
72
|
9
|
Survival (metastasis)
|
10
|
Male
|
59
|
ccRCC
|
G3
|
T1bN0M0
|
I
|
71
|
12
|
Survival (metastasis)
|
11
|
Male
|
55
|
ccRCC
|
G1
|
T1bN0M0
|
I
|
74
|
74
|
Survival
|
12
|
Male
|
62
|
ccRCC
|
G2
|
T1bN0M0
|
I
|
74
|
74
|
Survival
|
13
|
Male
|
54
|
ccRCC
|
G2
|
T1aN0M0
|
I
|
74
|
74
|
Survival
|
14
|
Male
|
60
|
ccRCC
|
G2
|
T1bN0M0
|
I
|
74
|
74
|
Survival
|
15
|
Male
|
48
|
ccRCC
|
G1
|
T1aN0M0
|
I
|
74
|
74
|
Survival
|
16
|
Male
|
68
|
ccRCC
|
G2
|
T1bN0M0
|
I
|
73
|
73
|
Survival
|
17
|
Male
|
48
|
ccRCC
|
G2
|
T1aN0M0
|
I
|
73
|
73
|
Survival
|
18
|
Male
|
73
|
ccRCC
|
G1
|
T1aN0M0
|
I
|
73
|
73
|
Survival
|
19
|
Female
|
58
|
ccRCC
|
G2
|
T1aN0M0
|
I
|
72
|
72
|
Survival
|
20
|
Male
|
48
|
ccRCC
|
G2
|
T1aN0M0
|
I
|
72
|
72
|
Survival
|
21
|
Male
|
49
|
PRCC
|
G2
|
T2N0M0
|
II
|
15
|
15
|
Death
|
22
|
Female
|
66
|
PRCC
|
G2
|
T3aN1M0
|
III
|
37
|
37
|
Death
|
23
|
Male
|
70
|
PRCC
|
G2
|
T3aN0M0
|
III
|
66
|
66
|
Death
|
24
|
Male
|
63
|
PRCC
|
G2
|
T3bN0M0
|
III
|
29
|
29
|
Death
|
25
|
Male
|
65
|
PRCC
|
G2
|
T1aN0M0
|
I
|
49
|
49
|
Death
|
26
|
Female
|
22
|
PRCC
|
G1
|
T1aN0M0
|
I
|
76
|
76
|
Survival
|
27
|
Female
|
60
|
PRCC
|
G2
|
T1aN0M0
|
I
|
74
|
74
|
Survival
|
28
|
Male
|
69
|
PRCC
|
G2
|
T1aN0M0
|
I
|
73
|
73
|
Survival
|
29
|
Male
|
59
|
PRCC
|
G2
|
T1aN0M0
|
I
|
71
|
71
|
Survival
|
30
|
Male
|
58
|
PRCC
|
G2
|
T1aN0M0
|
I
|
69
|
69
|
Survival
|
31
|
Female
|
49
|
ChRCC
|
NA
|
T2N0M0
|
II
|
86
|
86
|
Survival
|
32
|
Male
|
64
|
ChRCC
|
NA
|
T1aN0M0
|
I
|
85
|
85
|
Survival
|
33
|
Female
|
37
|
ChRCC
|
NA
|
T1aN0M0
|
I
|
85
|
85
|
Survival
|
34
|
Male
|
36
|
ChRCC
|
NA
|
T1bN0M0
|
I
|
84
|
84
|
Survival
|
35
|
Female
|
54
|
ChRCC
|
NA
|
T1aN0M0
|
I
|
84
|
84
|
Survival
|
36
|
Female
|
52
|
ChRCC
|
NA
|
T1aN0M0
|
I
|
82
|
82
|
Survival
|
37
|
Female
|
75
|
ChRCC
|
NA
|
T1aN0M0
|
I
|
78
|
78
|
Survival
|
38
|
Male
|
40
|
ChRCC
|
NA
|
T1bN0M0
|
I
|
77
|
77
|
Survival
|
39
|
Female
|
36
|
ChRCC
|
NA
|
T1bN0M0
|
I
|
77
|
77
|
Survival
|
40
|
Female
|
49
|
ChRCC
|
NA
|
T1bN0M0
|
I
|
76
|
76
|
Survival
|
- RCC renal cell carcinoma, TNM tumor-node metastasis stage, AJCC American Joint Committee on Cancer, OS overall survival, DFS disease-free survival, ccRCC clear cell renal cell carcinoma, PRCC papillary renal cell carcinoma, ChRCC chromophobe renal cell carcinoma, NA not available
- aThe 7th edition of the AJCC Cancer Staging Manual was used